The company's NExMods™ Platform utilizes the cell's normal protein regulation systems to eliminate disease-causing proteins. This novel approach, known as "molecular glues," has the potential to deliver impactful medicines in various therapeutic areas, including oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. F5 Therapeutics' research focuses on signaling pathways for stem cells during embryonic development and maintaining homeostasis and regeneration in adults. Their goal is to address cancers where traditional treatments have been ineffective due to wnt alterations and expand into multiple indications beyond oncology. F5 Therapeutics is based in San Diego, California.